Anteris Technologies Limited news
Anteris Technologies` Wayne Paterson provides an overview of a proposal that`s landed on the company`s desk, which asks it to consider a merger with NASDAQ-listed special purpose acquisition company Medicus Sciences Acquisition Corp. It`s still early days for the proposal, but if a transaction goes through, the merged entity would have at least US$50 million in cash, plus the existing funds held by the company. Moving ahead, AVR plans to do the math and weigh up the proposal`s r
- Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise
- On Thursday, the company entered a trading halt, pausing shares until Monday, August 2
- It is unknown how much the company is planning to raise or where the funds will be spent
- On the market, Anteris last traded at $8.59 per share
On Thursday, the company e
Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces the appointment of the internationally recognized Interventional Cardiologist, Dr Chris Meduri MD MPH, as its Chief Medical Officer (CMO).
Dr Meduri is a recognized leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees.
He has performed first-in-US and first-in-world procedures, led enrollment in many trials
Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces its submission at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference at Orlando, Florida, United States was accepted into the innovation session.
The TCT conference, running from November 4 to 6, is the largest and most prestigious Interventional cardiology meeting held each year and will return to an “in-person” meeting format.
The innovation component of TCT is reserv
Anteris reports successfully implanting five TAVR patients during the week of 14 November 2021 in a first-in-human (FIH) study to assess the DurAVR THV system for treating severe aortic stenosis. The study was carried out at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
The transcatheter aortic valve replacement procedures for all five patients were successful and without any complications. An additional five patients are planned for treatment in the first quarter of 2022 t